Ornithine News and Research

RSS

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today a multi-year research and development collaboration and exclusive licensing agreement with Sanofi Pasteur, the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five undisclosed infectious disease pathogens.

11 Jun 2018

People with major depressive disorder have reduced arginine levels, study shows

People suffering from major depressive disorder, MDD, have reduced arginine levels, a new study from the University of Eastern Finland shows. Arginine is an amino acid which the body uses to produce, e.g., nitric oxide.

21 Feb 2018

Computational approach can help identify chemoresistant potential targets in cancer stem cells

In cancer, one of the most important features is the methylation of deoxycytosine to form 5-methylcytosine (5mC). DNA methylation is a process by which methyl groups (structural units of organic compounds consisting of three hydrogen atoms bonded to a carbon atom) are added to the DNA molecule.

30 Jan 2018

New gene cut-and-paste methods help correct disease-causing mutation in animal model

For the first time, researchers have treated an animal model of a genetic disorder using a viral vector to deliver genome-editing components in which the disease- causing mutation has been corrected.

3 Feb 2016

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

30 Mar 2015

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences.

7 Jan 2015

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement.

4 Dec 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Researchers discover unrecognized mechanism by which PI3K sustains proliferation of cancer cells

New research published today in the Biochemical Journal describes the discovery of a new cancer target.

28 Feb 2013

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.

16 Dec 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

Fralin Life Science Institute professor receives grant from NSF to elucidate research on fungi

Pablo Sobrado, assistant professor of biochemistry with the Fralin Life Science Institute at Virginia Tech, has received a $1.1 million grant from the National Science Foundation (NSF) to advance his research on the mechanism of iron acquisition in fungi and mycobacteria.

19 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

A new Phase I clinical trial sponsored by the Vermont Cancer Center at the University of Vermont and Fletcher Allen Health Care has opened to test the investigational drug DFMO, or alpha-difluoromethylornithine, as a treatment for the pediatric cancer neuroblastoma.

15 Apr 2010

Researchers find novel use for old compound in cancer treatment

The compound, alpha-difluoromethylornithine or DFMO, targets the activity of a specific enzyme and, even in very limited doses, is effective in protecting against the malignancy in animal models.

19 Jan 2009

Difluoromethylornithine may affect Barrett's esophagus

"While there was a suggestion that difluoromethylornithine (DFMO) may influence the extent of Barrett's dysplasia, this finding is very preliminary and further study of this agent in a larger number of patients is needed," said Frank A. Sinicrope, M.D., professor of medicine and oncology at the Mayo Clinic, Rochester, MN.

16 Nov 2008

Ornithine News and Research

Translate Bio collaborates with Sanofi to develop mRNA vaccines for infectious diseases

People with major depressive disorder have reduced arginine levels, study shows

Computational approach can help identify chemoresistant potential targets in cancer stem cells

New gene cut-and-paste methods help correct disease-causing mutation in animal model

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Researchers discover unrecognized mechanism by which PI3K sustains proliferation of cancer cells

Ocera completes two studies of OCR-002 in patients with hyperammonemia, hepatic encephalopathy

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

Fralin Life Science Institute professor receives grant from NSF to elucidate research on fungi

New research on use of medicine, diet to prevent UV-induced skin cancer

Phase I clinical trial of DFMO initiated to treat children with neuroblastoma

Researchers find novel use for old compound in cancer treatment

Difluoromethylornithine may affect Barrett's esophagus

Diabetes effects sperm quality

Biomarkers allow doctors to match therapy to patient

Drugs that block the enzyme Odc prevent the onset of cancers

Major step forward in using saliva to detect oral cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News